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ABSTRACT
Objective To evaluate the relative short term safety and
intermediate term efficacy of carotid endarterectomy
versus carotid artery stenting.
Design Systematic review and meta-analysis.
Data sources BIOSIS, Embase, Medline, the Cochrane
central register of controlled trials, International
Pharmaceutical Abstracts database, ISI Web of Science,
and Google scholar and bibliographies, from 1 January
1990 to 25 July 2009.
Study selection Randomised controlled trials comparing
carotid endarterectomy with carotid artery stenting in
patients with carotid artery stenosis with or without
symptoms.
Data extraction Primary end point was a composite of
mortality or stroke. Secondary end points were death,
stroke, myocardial infarction, or facial neuropathy (as
individual end points), and mortality or disabling stroke
(as a composite end point).
Data synthesis 11 trials were included (4796 patients);
10 reported on short term outcomes (n=4709) and nine
on intermediate term outcomes (1-4 years). The
periprocedural risk of mortality or stroke was lower for
carotidendarterectomy(oddsratio0.67,95%confidence
interval 0.47 to 0.95; P=0.025) than for carotid stenting,
mainly because of a decreased risk of stroke (0.65, 0.43
to1.00;P=0.049),whereastheriskofdeath(1.14,0.56to
2.31; P=0.727) and the composite end point mortality or
disabling stroke (0.74, 0.53 to 1.05; P=0.088) did not
differsignificantly.Theoddsofperiproceduralmyocardial
infarction (2.69, 1.06 to 6.79; P=0.036) or cranial nerve
injury (10.2, 4.0 to 26.1; P<0.001) was higher in the
carotid endarterectomy group than in the carotid stenting
group. In the intermediate term, the two treatments did
not differ significantly for stroke or death (hazard ratio
0.90, 95% confidence interval 0.74 to 1.1; P=0.314).
Conclusions Carotid endarterectomy was found to be
superiortocarotidarterystentingforshorttermoutcomes
but the difference was not significant for intermediate
term outcomes; this difference was mainly driven by non-
disabling stroke. Significantly fewer cranial nerve injuries
and myocardial infarctions occurred with carotid artery
stenting.
INTRODUCTION
Carotid stenosis is responsible for around 20% of
strokes in the adult population.
1 Treatment of carotid
stenosisthereforeliesindecreasingtheriskofstrokeor
strokerelateddeaths.
2Themain treatmentis currently
carotid endarterectomy, a procedure that has been
showntobesuperiortomedicaltherapyinthepreven-
tionofstrokeanddeathinpatientswithcarotidstenosis
with and without symptoms.
3 Carotid angioplasty or
carotid artery stenting has been emerging as a newer
and less invasive alternative. Initial studies indicate
that this approach is feasible, safe, and effective.
However, the results of randomised controlled trials
comparing carotid artery stenting with carotid endar-
terectomy are ambiguous.
45A recent meta-analysis of
randomisedcontrolledtrialsreportedanincreasedrisk
ofstrokeordeathwithin30daysofcarotidarterystent-
ing compared with carotid endarterectomy.
6 In addi-
tion, a newer large observational study
7 and a
multicentre randomised controlled trial
8 found a
higher periprocedural (<30 days) incidence of stroke
with carotid artery stenting compared with carotid
endarterectomy.Inthisobservationalstudy,treatment
allocation was not random and therefore the study is
prone to confounding
9; patients at high surgical risk
underwent carotid artery stenting and had inherently
higher risks of myocardial infarction and death.
We evaluated the short term (periprocedural) safety
and intermediate term efficacy of carotid artery stenting
versus carotid endarterectomy for stroke or death in
patients with carotid stenosis with or without symptoms.
METHODS
The study was done according to the preferred report-
ing items for systematic reviews and meta-analyses
(PRISMA) guidelines.
10 Two authors (HSG and PM)
plannedanddesignedthestudyandcreatedanelectro-
nic database with variables of interest (Microsoft
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BMJ | ONLINE FIRST | bmj.com page 1 of 9Excel). We defined the primary and secondary end
points, variables of interest, and search strategy (data-
bases, sources for unpublished data) in a strategy out-
line (details available on request).
We included randomised controlled trials that com-
paredcarotidendarterectomywithcarotidarterystent-
ing (with and without the use of cerebral protective
devices)inpatientswithcarotidstenosiswithandwith-
out symptoms.The outcomes of primary interest were
death and stroke at least one year after a procedure as
well as myocardial infarction within 30 days of a pro-
cedure. We included randomised controlled trials
regardless of their publication status, language, size,
or duration of follow-up.
We searched BIOSIS, Embase, Medline, the
Cochrane central register of controlled trials, Inter-
national Pharmaceutical Abstracts database, ISI Web
ofScience,andGooglescholarfrom1January1990to
25 July 2009. See web extra table 1 for details of the
search strategy on Medline. We used similar but
adapted search terms for the other databases.
We also searched abstract lists and conference pro-
ceedings of the 2006-9 scientific sessions of the
American College of Cardiology, the European
Society of Cardiology, the 2006-8 proceedings of the
Transcatheter Cardiovascular Therapeutics, and the
AmericanHeartAssociation.Wealsoconsideredpub-
lished review articles, editorials, and internet based
sources of information (www.tctmd.com, www.the
heart.org). Medical subject headings and keyword
searches included the terms carotid endarterectomy,
carotid artery stenting, stroke, myocardial infarction,
and death. We reviewed the reference lists of selected
articlesforotherpotentiallyrelevantcitations.Authors
of selected studies were contacted for further informa-
tion if necessary, such as the hazard ratios for inter-
mediate term data.
Study selection
Two investigators (HSG and PM) identified potential
studies and assessed them for eligibility using a two
step process. Firstly, they independently reviewed the
titlesandabstractsofallcitationstoidentifypotentially
relevant studies and to exclude duplicates. Secondly,
they reviewed the corresponding publications in full
text to assess if studies met the inclusion criteria—that
is,randomisedcontrolledtrials thatdirectlycompared
carotid endarterectomy with carotid artery stenting;
had stroke or death, or both as end points; and had at
least30daysoffollow-up.Reviewerswerenotblinded
to study authors or outcomes. The final inclusion of
studies was based on agreement between the
reviewers.
Data extraction and quality assessment
Three investigators (PM, UT, and HSG) used the stan-
dardised extraction database (Microsoft Excel) to
extract information on outcome (numbers of patients,
event rates for periprocedural and intermediate term
death and stroke, both as single end points and as a
composite end point) with hazard ratios; periproce-
dural death or disabling stroke (composite end point);
myocardialinfarction;andfacialneuropathyaswellas
Stage 1: Review of
  title and abstract
Stage 2: Full text
  review or contact
  with study authors
Study abstracts screened after removing duplicates (n=114)
Randomised controlled trials included in meta-analysis (n=11)
Excluded (n=76)
Potentially relevant studies identified (n=143):
  Search of databases (n=129)
  Search through other sources (n=14)
Full text articles assessed for eligibility (n=38)
Excluded; not randomised (n=27)
Fig 1 | Outline of search and selection strategy
Characteristics of studies included in meta-analysis
Study (years)
Short term/
intermediate
term data Interventions (No of patients)
Duration of
follow-up
Proportion of patients (%)
Mean age
(years)
Distal
protection
Stent
implanted Asymptomatic
Naylor et al
29 (1998) Yes/no Carotid endarterectomy (n=12) v carotid artery stenting (n=11) 30 days 0 100 0 66.7 v NA
Wallstent
26 (2001) Yes/yes Carotidendarterectomy(n=112)vcarotidarterystenting(n=107) 12 months 0 100 0 70 v 66.5
CAVATAS
25 (2001) Yes/yes Carotidendarterectomy(n=253)vcarotidarterystenting(n=251) 23.4 months 0 26 3 67 v 67
Brooks et al
27 (2001) Yes/yes Carotid endarterectomy (n=51) v carotid artery stenting (n=53) 24 months 0 100 0 69.6 v 66.4
Brooks et al
30 (2004) Yes/no Carotid endarterectomy (n=42) v carotid artery stenting (n=43) 48 months 0 100 100 69.9 v 66.6
SAPPHIRE
22 33 (2004/8) Yes/yes Carotidendarterectomy(n=167)vcarotidarterystenting(n=167) 36 months 95.6 100 71.2 72.6 v 72.5
EVA-3S
21 32 (2006/8) Yes/yes Carotidendarterectomy(n=262)vcarotidarterystenting(n=265) 42.5 months 92 100 0 70.2 v 69.1
SPACE
23 (2007) Yes/yes Carotidendarterectomy(n=584)vcarotidarterystenting(n=599) 48 months 27 100 0 68.2 v 67.6
BACASS
28 (2006) Yes/yes Carotid endarterectomy (n=10) v carotid artery stenting (n=10) 48 months 100 100 0 71 v 69
Steinbauer etal
24 (2008) No/yes Carotid endarterectomy (n=44) v carotid artery stenting (n=43) 65 months 0 100 0 68.4 v 67.9
ICSS
8 (2009) Yes/no Carotidendarterectomy(n=857)vcarotidarterystenting(n=853) 30 days 80 100 0 NA
NA=not available. CAVATAS=Carotid and Vertebral Artery Transluminal Angioplasty Study; SAPPHIRE=Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy;
EVA-3S=Endarterectomy Versus Angioplasty in patients with Symptomatic Severe carotid Stenosis; SPACE=Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus
Endarterectomy; BACASS=Basel Carotid Artery Stenting Study; ICSS=International Carotid Stenting Study.
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proportion of patients requiring distal protection, pro-
portion requiring a stent, and proportion without or
with symptoms). We assessed trial quality by evaluat-
ing randomisation and allocation concealment, inten-
tion to treat analysis, blinded assessment of outcome
measures, premature stopping of patient enrolment,
and reporting about dropouts, but without using a
quality score given limitations inherent to such an
approach (see web extra table 3).
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Data synthesis and analysis
To estimatethe pooledodds ratiofor carotid endarter-
ectomycomparedwithcarotidarterystentingwecom-
binedthedataonshorttermbinaryoutcomesfromthe
selected studies using a random effects model with
inversevarianceweights.Whentheestimateofthehet-
erogeneity variable is zero, the random effect model
coincides with a fixed effect meta-analysis. Because
several P values were around the predefined signifi-
cance threshold of 0.05, we carried out sensitivity ana-
lyses using alternative analytical models for these
variables. The odds ratios were recalculated using
three approaches: on the basis of the Hartung-Knapp
variance estimates (R package “metafor”), which are
usually more conservative but have better coverage
probabilities
12;a n“exact” likelihood approach (bino-
mial-normalhierarchicalmodel;SAS,Procnlmixed)
13
; and the Peto method.
To further evaluate trends over time we used a
cumulative meta-analytical model (random effects).
This analysis cumulates the effects stepwise over time
by integrating newly published studies sequentially
according to the date of publication.
14 To account for
varying time to event for intermediate term follow-up,
we used hazard ratios of time to events (R package
“meta,” function metagen). This approach accounts
for differential follow-up intervals and patients who
were lost to follow-up. All analyses were done on an
intentiontotreatbasis.Whenaneventdidnotoccurin
one group we used continuity correction.
15 We evalu-
atedthepresenceofheterogeneityacrosstrialswiththe
QandHiggins’sandThompson’sI
2statistics.I
2canbe
interpreted as the percentage of variability due to het-
erogeneity between studies rather than to sampling
error. To assess the effect of individual studies on the
summaryestimateofeffect,wecarriedoutaninfluence
analysis,inwhichwerecalculatedthepooledestimates
by omitting one study at a time. We assessed publica-
tion bias visually (funnel plot) and by formal tests
(Egger’stestofinterceptandthearcsinetest).
16-18Aver-
age weighted incidence of events is presented for both
treatments; calculation was based on a random effect
analysisusingthe inversevariancemethodand a Free-
man-Tukey double arcsine transformation.
19 All data
are presented with 95% confidence intervals. Two
investigators (GK and PM) carried out analyses inde-
pendently using R, version 2.9.0, package meta and
metaphor, and SAS version 9.1 (Proc nlmixed).
1320
RESULTS
Of58fulltextarticlesreviewed,11trialsmettheinclu-
sion criteria (fig 1).
821-30 Ten reported on short term
outcomes and nine on intermediate term outcomes;
among those, one reported exclusively on inter-
mediate term outcomes.
24 The Carotid Revasculariza-
tion using Endarterectomy or Stenting Systems
(CARESS) trial was not included in this analysis as
treatment assignment was not randomised.
31 The
table summarises the characteristics of the 11 trials.
Periprocedural outcome
The weighted average incidence of periprocedural
death or stroke was 5.4% (95% confidence interval
4.0% to 7.0%) for carotid endarterectomy and 7.3%
(4.9% to 10.1%) for carotid artery stenting. The risk
was significantly lower for carotid endarterectomy
compared with carotid artery stenting (odds ratio
0.67, 95% confidence interval 0.47 to 0.95; P=0.025;
I
2=37.4%; P=0.119) (fig 2). The studies defined peri-
proceduralstrokedifferently.TheCarotidandVerteb-
ral Artery Transluminal Angioplasty Study
(CAVATAS)onlycounteda stroke eventifsymptoms
lasted longer then seven days.
25 Other studies, such as
the Basel Carotid Artery Stenting Study (BACASS),
definedstrokeasaneurologicaldeteriorationwithper-
sistence over 24 hours.
28 Neither funnel plot, Egger’s
plot (see web extra fig 1), nor formal tests (Egger’s and
arcsine test) indicated potential publication bias or
small study bias (P=0.932 and P=0.989, respectively).
Further analyses to evaluate heterogeneity of study
results showed an important change in the compara-
tive efficacy of the two procedures over time. The dis-
tinct inferiority of carotid artery stenting compared
withcarotidendarterectomyshownearlyonby cumu-
lativemeta-analysis diminishedover timewhen newer
trials were added sequentially (see web extra fig 2).
Another factor was the high number of trials
  Naylor et al 1998
29
  Wallstent 2001
26
  CAVATAS 2001
25
  Brooks et al 2001
27
  Brooks et al 2004
30
  SAPPHIRE 2004/8
22 33
  EVA-3S 2006/8
21 32
  SPACE 2006
23
  BACASS 2007
28
  ICSS 2009
8
Random effects model
0.05 (0.00 to 0.99)
0.34 (0.12 to 0.98)
0.99 (0.55 to 1.78)
3.18 (0.13 to 79.83)
1.15 (0.41 to 3.25)
0.38 (0.18 to 0.81)
0.84 (0.54 to 1.31)
3.32 (0.12 to 91.60)
0.57 (0.39 to 0.85)
0.67 (0.47 to 0.95)
12/0
112/5
253/25
51/1
42/0
167/8
262/10
584/38
10/1
857/43
2350/131
0.2 0.5 1 2 5
Study
Favours
carotid
endarterectomy
Favours
carotid artery
stenting
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Carotid
endarterectomy
11/5
107/13
251/25
53/0
43/0
167/7
265/25
599/46
10/0
853/72
2359/193
Carotid
artery stenting
No of patients/No of events
Fig 2 | Forest plot of odds ratios of risk for composite of stroke or death within 30 days of
carotid endarterectomy versus carotid artery stenting. ICSS also included myocardial
infarctions (three for stenting, four for endarterectomy) in this end point. See footnote to table
for full title of studies
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before they reached their predefined sample size
(table).
21-232629 These trials showed more pronounced
superiority of carotid endarterectomy over carotid
artery stenting (odds ratio 0.56, 0.30 to 1.0; P=0.058),
whereas the difference was smaller in studies com-
pleted formally (0.76, 0.47 to 1.23; P=0.261).
Secondary end points
Periproceduralstrokewasreportedinninestudies,two
ofwhichdidnotobserveanystrokeduringthisperiod.
The average weighted incidence of stroke was 4.2%
(95% confidence interval 2.7% to 6.1%) for carotid
endarterectomyversus5.7%(3.0% to9.2%)forcarotid
artery stenting. The risk of stroke was significantly
lower for carotid endarterectomy (odds ratio 0.65,
95% confidence interval 0.43 to 1.00; P=0.049;
I
2=48.4%, P=0.071) (fig 3).
Periprocedural mortality was reported as an end
point in eight trials; in three, no death was observed
in either group.
8232527-3032 The average weighted inci-
dence of death was 1.4% (95% confidence interval
0.08% to 2.1%) for carotid endarterectomy and 1.2%
(0.7% to 1.8%) for carotid artery stenting. Overall,
there was no significant difference between patients
treated with carotid endarterectomy versus carotid
artery stenting (odds ratio 1.14, 95% confidence inter-
val 0.56 to 2.31; P=0.727; I
2=0%; P=0.697) (fig 3).
Data on the composite end point of periprocedural
disabling stroke or death was available from eight
trials; no event was observed in two.
8232527-3032 The
weightedaverageeventratewas2.9%(95%confidence
interval 1.9% to 4.3%) for carotid endarterectomy ver-
sus 3.8% (2.3% to 5.7%) for carotid artery stenting. In
the direct comparison, this difference was not signifi-
cant (odds ratio 0.74, 95% confidence interval 0.53 to
1.05; P=0.088; I
2=0%; P=0.600). For the Stent-Sup-
ported Percutaneous Angioplasty of the Carotid
ArteryversusEndarterectomy(SPACE)trial,thecom-
posite end point was defined as ipsilateral disabling
stroke or death; for the International Carotid Stenting
Study(ICSS),onlyperprotocoldatawereavailablefor
thisendpointandthesedatawereusedinsteadofinten-
tion to treat data.
The rate of periprocedural myocardial infarction
was reported in four trials.
25283233 The weighted aver-
age infarction rate was 2.6% (95% confidence interval
0.4% to 6.3%) for carotid endarterectomy versus 0.9%
(0.05% to 2.9%) for carotid artery stenting. The risk of
infarctionwassignificantlyhigherinthecarotidendar-
terectomy group (odds ratio 2.69, 95% confidence
interval 1.06 to 6.79; P=0.036; I
2=0%; P=0.700) (fig 4).
Six studies reported on periprocedural cranial
facial neuropathy; no event occurred in one
study.
252728303233 The average weighted event rate
was 7.5% (95% confidence interval 5.8% to 9.4%) for
carotid endarterectomy versus 0.45% (0.01% to 1.0%)
for carotid artery stenting. Overall, the risk was higher
in the carotid endarterectomy group(oddsratio 10.25,
95% confidence interval 4.02 to 26.13; P<0.001;
I
2=0%; P=0.754) (fig 5).
Sensitivity analyses
Analyses of periprocedural risk for major end points
provided odds ratio with confidence intervals close to
1.0. Thus, reanalyses of the three end points death and
stroke, death, and stroke were done by two additional
meta-analytical approaches deemed meaningful in
estimating variances (see web extra table 2). The
pointestimatesfortheoddsratioweresimilarandcon-
fidence intervals even narrower for most end points.
The influence of individual studies was tested by rea-
nalyses,omittingonestudyatatime.Nostudyshowed
an overwhelming influence on the overall odds ratio
estimates (data not presented).
Data from the ICSS trial also included myocardial
infarction in the primary end point death or stroke;
corresponding data without myocardial infarction
were not available for the intention to treat analysis
but were available as a per protocol analysis. Reanaly-
sisusingtheperprotocoldataproducedasimilarresult
(odds ratio 0.63, 95% confidence interval 0.42 to 0.94;
P=0.025; I
2=47.2%; P=0.056).
We also carried out an analysis including trials that
only enrolled patients with carotid stenosis who had
symptoms while excluding the SAPPHIRE (Stenting
and Angioplasty with Protection in Patients at High
Stroke
  Naylor et al 199829
  CAVATAS 200125
  Brooks et al 2001
27
  Brooks et al 2004
30
  SAPPHIRE 2004/8
22 33
  EVA-3S 2006/8
21 32
  SPACE 200623
  BACASS 200728
  ICSS 2009
8
Random effects model
0.05 (0.00 to 0.99)
1.17 (0.61 to 2.26)
0.83 (0.25 to 2.77)
0.36 (0.16 to 0.78)
0.81 (0.51 to 1.27)
3.32 (0.12 to 91.60)
0.50 (0.33 to 0.77)
0.65 (0.43 to 1.00)
12/0
253/21
51/0
42/0
167/5
262/9
584/36
10/1
857/34
2238/106
0.2 0.5 1 2 5
Study
Favours
carotid
endarterectomy
Favours
carotid artery
stenting
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Carotid
endarterectomy
11/5
251/18
53/0
43/0
167/6
265/24
599/45
10/0
853/65
2252/163
Death
  Naylor et al 199829
  CAVATAS 200125
  Brooks et al 2001
27
  Brooks et al 200430
  SAPPHIRE 2004/822 33
  EVA-3S 2006/821 32
  SPACE 200623
  BACASS 200728
Random effects model
0.56 (0.16 to 1.94)
3.18 (0.13 to 79.83)
2.02 (0.37 to 11.21)
1.52 (0.25 to 9.19)
1.28 (0.34 to 4.81)
1.14 (0.56 to 2.31)
12/0
253/4
51/1
42/0
167/4
262/3
584/5
10/0
1381/17
11/0
251/7
53/0
43/0
167/2
265/2
599/4
10/0
1399/15
Carotid
artery stenting
No of patients/No of events
Fig 3 | Forest plot of odds ratios of 30 day risk for stroke or death (individual end points) within
30 days of carotid endarterectomy versus carotid artery stenting. ICSS was not included in this
analysis for death because overall mortality data based on an intention to treat analysis were
not available See footnote to table for full title of studies
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2233 and Brooks et al’s
30
trial that predominantly or exclusively consisted of
asymptomatic patients. For the primary end point the
odds ratio for carotid endarterectomy versus carotid
artery stenting was similar (0.63, 0.44 to 0.92;
P=0.017).
Intermediate term outcomes
Theriskfortheintermediatetermcompositeendpoint
strokeordeathdidnotdiffersignificantlybetweencar-
otid endarterectomy and carotid artery stenting.
Among the nine trials reporting on long term results,
hazard ratios were available for the four larger trials;
data for the SAPPHIRE trial
2233 were provided by the
study investigators. For the data of the CAVATAS
trial,
25 the hazard ratios were controlled for sex, age,
and trial centre, whereas the other studies provided
unadjusted hazard ratios; furthermore, the hazard
ratios of the CAVATAS trial were based on deaths
and disabling strokes. Data on the ICSS trial
8 were
not considered because the maximum follow-up time
was limited to 120 days. No difference was found
between carotid artery stenting and carotid endarter-
ectomy (hazard ratio 1.11, 95% confidence interval
0.91 to 1.35; P=0.315; I
2=0%; P=0.400) (fig 6).
Wealsoanalysedeventdatabasedontheclassicinci-
dence of events (as for short term data). Binary data
(events and total number of patients per group) were
availableforninetrialsanddidnotshowanydifference
in outcome (odds ratio 0.87, 95% confidence interval
0.71 to 1.07; P=0.190; I
2=0%; P=0.432) (fig 7).
The risk of stroke in the intermediate term was not
significantly different between the two treatments in
the four studies providing information on time to
event analyses (hazard ratio 0.86, 95% confidence
interval 0.67 to 1.10; P=0.216; I
2=4.3%; P=0.371).
Theclassicanalysisbasedoneighttrialsprovidingbin-
arydataonthisendpoint
252728303233gaveanoddsratio
of0.78(95%confidenceinterval0.56to1.09);P=0.151
(I
2=12.3%; P=0.337). Intermediate term mortality did
not differ significantly for carotid endarterectomy
compared with carotid artery stenting for the trials
(hazard ratio 1.09, 0.76 to1.57; P=0.625; I
2=6.3%;
P=0.306), but time to event based data were available
for only two trials. The classic analysis based on seven
trials providing binary data on this end
point
252728303233 gave an odds ratio of 1.04 (95% con-
fidence interval 0.78 to 1.38); P=0.779 (I
2=0%;
P=0.856).
DISCUSSION
This meta-analysis indicates that carotid endarterect-
omyisassociatedwithbetterperiproceduraloutcomes
thancarotidarterystenting.Thisdisparitywasprimar-
ilydrivenbyadifferenceinriskofproceduralnon-dis-
abling stroke, which seemed to be higher in patients
treated with carotid artery stenting. Conversely, the
risk of facial neuropathy and periprocedural myo-
cardial infarction was higher with carotid endarterect-
omy.Intheintermediatetermtolongterm,primaryor
secondary end points did not differ significantly, sug-
gesting similar efficacy of the two procedures.
Since carotid revascularisation is carried out solely
for the prevention of future events, the rate of proce-
dural complications (especially stroke) is a key driver
ofthe risk-benefitratio.Thetrade-offbetweenthe pro-
cedural risk and the longer term benefit has to be eval-
uated carefully; this also has to be kept in mind when
interpreting trials comparing procedures for treating
carotid artery stenosis; especially since none of the
trials included a best medical therapy only group.
Carotid endarterectomy has been shown to reduce
the overall risk for stroke and death compared with
medical treatment in patients with relevant carotid
artery stenosis both with symptoms
34 and without
symptoms
35. Based on these trials, an acceptable
upper limit of perioperative rate for stroke or death
has been determined to be around 3% for asympto-
matic patients
35 and 6% for patients with
symptoms.
3637 Congruent with this, our analysis of
mainly patients with symptoms showed a procedure
related event rate of 5.4% for carotid endarterectomy.
For carotid artery stenting, the average perioperative
eventratewas7.3%inouranalysis.Inthisperspective,
evaluation of expected excessbenefit for anindividual
patient is difficult and has to be based on his or her
estimated baseline risk of stroke without treatment
and on life expectancy. Moreover, the efficiency of
medical treatment has probably improved, since
most of the pivotal trials on carotid endarterectomy
didnotprescribetotheaggressiveriskfactorreduction
that would be considered standard today for patients
with established atherosclerosis.
3839
Failuretoaccountfortrendsinoutcomesovertimeis
a major limitation of a meta-analysis evaluating an
emerging technology. This is evident in the specialty
of cardiovascular medicine as the outcomes with caro-
tid artery stenting have continued to improve and the
results reported in recent registrieshave been superior
to those in most of the trials included in the meta-ana-
lysis. Whereas the average 30 day rate for stroke or
death was 7.3% in the included trials, the Emboshield
and Xact Post Approval Carotid Stent Trial (EX) reg-
istry (which included 2145 high risk surgical patients)
and the Carotid ACCULINK/ACCUNET Post
  CAVATAS 2001
25
  SAPPHIRE 2004/8
22 33
  EVA-3S 2006/8
21 32
  BACASS 2007
28
Random effects model
7.03 (0.36 to 136.76)
2.51 (0.86 to 7.29)
2.03 (0.18 to 22.53)
2.69 (1.06 to 6.79)
253/3
167/12
262/2
10/0
692/17
0.2 0.5 1 2 5
Study
Favours
carotid
endarterectomy
Favours
carotid artery
stenting
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Carotid
endarterectomy
251/0
167/5
265/1
10/0
693/6
Carotid
artery stenting
No of patients/No of events
Fig 4 | Forest plot of odds ratios of 30 day risk for myocardial infarction for carotid
endarterectomy versus carotid artery stenting. See footnote to table for full title of studies
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included 4175 patients) showed 30 day rates for stroke
or death of only 4.1% and 3.4%, respectively.
40 This
may be attributed to a learning curve in the emerging
technique of carotid artery stenting with improvement
in equipment design, optimisation of patient selection,
adequate training of operators, and better attention to
pharmacotherapy (see web extra fig 2). This learning
curve has been a major drawback for some of the lar-
gest trials in carotid artery stenting where a significant
proportion of operators had limited experience, 39%
of patients in the Endarterectomy Versus Angioplasty
in patients with Symptomatic Severe carotid Stenosis
(EVA-3S) trial were treated by doctors with modest
experience of the procedure
41 and use of emboli pro-
tection devices and dual antiplatelet therapy was not
universal.
2332
Thiswouldsuggestthatcarotidarterystentingascar-
ried out in most patients included in the meta-analysis
would be expected to be inferior to carotid endarter-
ectomy, whereas the intermediate term outcome
wouldbesimilar.Thesefindingshaveimportantimpli-
cations for patients undergoing carotid revascularisa-
tion. Currently, use of carotid artery stenting in the
United States is restricted by Centers for Medicare
and Medicaid Services guidelines to patients at high
risk for carotid endarterectomy or those enrolled in
clinical trials. The results of this meta-analysis suggest
that it may be premature to consider any revision to
theseguidelines.Furthermore,theconsistentlyinferior
short term results of carotid artery stenting as done in
these studies suggests a need for a strategy aimed at
minimising the risk of procedural stroke. This would
involve adequate case selection, rigorous training and
credentialing of operators, appropriate strategies to
reduceproceduralembolicphenomenon,andsuitable
drugs. Current trials must ensure that such mechan-
isms are in place and that patientsare clearlyinformed
oftherisksinundergoingcarotidarterystentingversus
carotid endarterectomy. It is worth noting that factors
rendering patients at high risk from carotid endarter-
ectomyarenotnecessarilyidenticaltothoseforcarotid
artery stenting. Although comorbidities are the major
riskfactorswithcarotidendarterectomy,carotidartery
stenting outcomes are mainly influenced by the anat-
omy of local vessels, and both factors have to be con-
sidered in treatment decision making.
42
Althoughtherehavebeenmultiplerecentmeta-ana-
lysis in carotid revascularisation,
643 our study signifi-
cantly extends the work because of a larger
population, a more robust methodology, and longer
term follow-up data. Earlier studies have erroneously
split composite end points from the SAPPHIRE
trial,
2233 which we confirmed from study authors.
Also, previous meta-analysis preferentially reported
on a fixed effect model instead of the more conserva-
tive random effect model, which is more appropriate
here owing to considerable study heterogeneity.
6
Furthermore, we used appropriate transformations to
generate weighted proportions for procedural compli-
cation rates.
Finally, we used time to event analysis for longer
term outcomes, and the pooled hazard ratio provides
a more accurate assessment of events compared with
odds ratios or risk ratios that ignore possible variation
intimetoeventsandincompletefollow-up.Thisispar-
ticularly relevant to events such as stroke or death
where an event early in the study would be consider-
ably more devastating than one occurring later.
Heterogeneity of study results
Even though heterogeneity of study results was mod-
erate, relevant aspects of dissimilarities in study
designs have to be considered. Most of the studies
excluded asymptomatic patients whereas one study
evaluated asymptomatic patients exclusively
30 and in
another trial two thirds of patients were
asymptomatic.
22 Moreover, average surgical risk of
the study populations were different; the SAPPHIRE
trial
22includedhighriskpatientsexclusively.Thistrial,
incontrastwithmostothers,foundasuperiorityofcar-
otid artery stenting over carotid endarterectomy. This
suggests that since intermediate term outcomes are
similaritmightbeappropriatetoselectarevascularisa-
tion strategy based on the procedural risk of patients.
However,exclusionofthesetwostudiesincludingpre-
dominantly asymptomatic patients did not change the
overall outcome of our analysis.
A major reason for heterogeneity between the stu-
dies was because almost half of the trials were stopped
prematurely, before the prespecified sample size was
reached. Early stopping can lead to overestimation of
treatment effects (stop at random high) as shown in
several previous analyses.
4445 For two of the early
stopped trials, however, the decision was not based
on differential outcomes but on problems with
funding
23 or recruitment,
22 whereas for three trials the
earlystoppingwasbasedonlargedifferencesinriskfor
the compared treatments.
212629 These three trials may
have led to some overestimation of the superiority of
carotidendarterectomy.Thisfacthighlightstheimpor-
tance of completion of currently ongoing trials—for
example, CREST (Carotid Revascularization
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Fig 5 | Forest plot of odds ratio of periprocedural (30 day) cranial nerve injuries for carotid
endarterectomy versus carotid artery stenting. See footnote to table for full title of studies
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(Asymptomatic Carotid Stenosis, Stenting versus
Endarterectomy Trial)—to define the best contempor-
ary carotid revascularisation strategy.
Furthermore, concomitant drug treatment differed
among the included trials. Earlier trials required
aspirintreatmentonly
29withnopretreatment,whereas
the Wallstent trial
26 used ticlopidine for four weeks
after the procedure, and more recent studies
20232428
used clopidogrel for about 2-4 weeks after the proce-
dure, often for 72 to 24 hours before the stenting pro-
cedure. This may be particularly relevant to the
periprocedural outcomes for carotid stenting where
inadequate platelet inhibition may predispose to
early thrombosis and embolisation with the attendant
hazard of stroke.
Limitations of the meta-analysis
Most of the patients in this meta-analysis had symp-
toms; asymptomatic patients were under-represented
and a generalisation to this population would be spec-
ulative.Asymptomaticpatients generallyhave a lower
procedural risk, but specific evidence for this group is
currently limited to one trial that did not observe an
eventineithergroup.
30Conceptually,preventivetreat-
ment of carotid artery disease rather than intervening
after a first cerebrovascular event would seem mean-
ingful, although a similar degree of prevention may be
achievedbyaggressivemedicaltherapy.Moredataon
this population are required, although contemporary
registrystudiessuggestapersistentlyhighriskofstroke
in asymptomatic patients with carotid stenosis.
46
Two of the included studies have only been pre-
sented at scientific meetings or published as abstracts
and did not undergo a rigorous peer review process.
Thequalityassessmentofthesestudiesisthereforelim-
ited. Exclusion of these trials from the analysis did not
changetheresults.Finally,thereareseverallimitations
of the included studies, which may have introduced a
systematic bias against carotid stenting and potentially
ledtoanoverestimationofthebenefitofcarotidendar-
terectomy. Firstly, the primary end point of most stu-
dieswasacompositeofdeathorstroke.Thisendpoint
has been used traditionally for most trials in the disci-
pline of carotid endarterectomy. This composite end
point seems meaningful as an efficacy end point but
neglectsimportantsafetyissuessuchasperiprocedural
myocardial infarction and cranial neuropathy. The
incidence of each of these events was less than 1% on
average for carotid stenting in the included trials
whereas for carotid endarterectomy the average inci-
dence for myocardial infarction was 2.6% and that for
cranialneuropathywas7.5%.Eventhoughmostofthe
cranialnerveneuropathiesaretransient,about4%per-
sist over several months and about 0.5% are
permanent.
47 Such injuries to the cranial nerve and
also myocardial infarctions can have an effect on a
patient’s quality of life similar to that after a stroke.
Future trials should consider the use of composite
end points that also include relevant safety end points.
Secondly, most included studies based their preproce-
dural assessment mainly on carotid duplex sonogra-
phy, which generally gives an insufficient assessment
ofthevesselanatomy.Vascularanatomyisakeydeter-
minant of periprocedural risk for carotid artery stent-
ing. However, the perioperative risk with carotid
endarterectomy is mainly defined by clinical risk fac-
tors that are usually available at first encounter with
patients and may have served to exclude high risk
patients from inclusion in a study. This could poten-
tially introduce a selection bias that disfavours carotid
stenting.Finally,mosttrialsrequiredextensiveexperi-
ence of the surgeons carrying out carotid endarterect-
omy, whereas the corresponding requirements for
interventionalistsdoingcarotidstentingwerelessstrin-
gent. The EVA-3S trials, for example, required sur-
geons to have carried out at least 25 procedures in the
previous year, whereas interventionalists had to have
carriedoutatleast12carotidstentingproceduresover-
all or only five if they had done 35 stentings of the
supra-aortic trunk; those who had less experience
could enrol patients with a tutor, who was required to
have carried out at least 12 procedures overall. Thus
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Fig 7 | Forest plot of odds ratios of intermediate term risk for composite of stroke or death as
binary outcomes, without considering time interval between intervention and event (Wallstent
trial
26 used an endpoint definition of “ipsilateral stroke, procedure-related death, or vascular
death within 1 year”)
  EVA-3S 2006/8
21 32
  SAPPHIRE 2004/8
22 33
  SPACE 200623
  CAVATAS 2001
25
Random effects model
1.39 (0.96 to 2.00)
0.86 (0.56 to 1.32)
1.11 (0.77 to 1.60)
1.03 (0.64 to 1.64)
1.11 (0.91 to 1.35)
0.75 1 1.5
Study
Favours
carotid
endarterectomy
Favours
carotid
artery
stenting
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
30
21.9
29.7
18.4
100.0
Weight
(%)
Fig 6 | Forest plot of hazard ratio of intermediate term risk for composite of stroke or death
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 9the lack of similar operator experience may have
biased the results against carotid stenting.
Conclusion
In our meta-analysis including 4796 patients with car-
otid stenosis predominantly with symptoms, carotid
endarterectomy was associated with a lower risk for
the primary end point of death or stroke. This differ-
encewasmainlydrivenbythe lowerincidenceofperi-
procedural non-disabling or minor strokes. A relevant
temporal impact exists indicating a continuously
improving outcome for the newer carotid artery stent-
ing approach compared with the longer established
carotid endarterectomy. We found no significant dif-
ferences in numbers of major or disabling strokes or
deaths, whereas significantly fewer cranial nerve inju-
ries and myocardial infarctions occurred with carotid
artery stenting. Intermediate term outcomes were not
significantly different between the two interventions.
Patients with symptoms requiring carotid revasculari-
sation should currently be offered carotid endarterect-
omy as first choice, with carotid artery stenting
reservedforpatientsathighsurgicalrisk.Trialsofcon-
temporarycarotidarterystentingversuscarotidendar-
terectomy are needed to better understand the role for
each treatment in patients with or without symptoms.
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